Published July 24, 2024 | Version v1
Dataset Open

Population Statistics on NCT02332590

Creators

  • 1. ROR icon Sanofi (Germany)

Description

Data presented as mean or median (change), in parts with quantiles (Q1, Q3) published by

C. Gaby, G. Burmester, V. Strand, J. Msihid, M. Zilberstein, T. Kimura, B. van Hoogstraten, S. H. Boklage, J. Sadeh, M. H. G. Neil and A. Boyapati, "Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes," Arthritis Research & Therapy, vol. 22, no. 1, p. 70, 2020.

Files

Files (32.4 kB)

Name Size Download all
md5:bfed5219dfdd4fc31ef271b1f90ff52f
11.1 kB Download
md5:02eaee6a05060408b0888e9fa56fb8e7
10.8 kB Download
md5:36e5e81b992f00f86fef00204f4861e7
10.5 kB Download

Additional details

Related works

Is version of
Dataset: 10.1186/s13075-020-02163-6 (DOI)

Dates

Accepted
2020-04-07

References

  • C. Gaby, G. Burmester, V. Strand, J. Msihid, M. Zilberstein, T. Kimura, B. van Hoogstraten, S. H. Boklage, J. Sadeh, M. H. G. Neil and A. Boyapati, "Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes," Arthritis Research & Therapy, vol. 22, no. 1, p. 70, 2020.